Indication and most important inclusion criteria
This European registry enrolls male or female patients from 18 years of age with a diagnosis of BCR-ABL positive CML in chronic phase (CP).
The registry will be available to all CML patients after at least two years of treatment with one or more tyrosine kinase inhibitor(s) (TKIs) at any prescribed dose as per routine clinical practice for a minimum of 24 months at registry entry.
Short description of intervention
The EUREKA registry will collect and evaluate medical data and molecular results of the assessment of residual disease (deep molecular response, MR4.5) in patients with chronic myeloid leukemia (CML) in chronic phase (CP).
Deep molecular response is assessed routinely in the course of treatment of CML. Additional blood sampling will not be required.
Assessment results and biomaterials will be collected, stored and evaluated by specialized laboratories (certified MR4.5 labs). The data analysis is aiming to show the availability of deep molecular response assessment for all CML patients in Europe.
Type of study
Other trial = epidemiological registry
European LeukemiaNet (ELN)
Scientific lead / contact
Prof. Dr. med. Andreas Hochhaus
Klinik Innere Medizin II
Study centers / principal investigators